Methods of determining levels of cleaved and/or intact kininogen

US11156612B2 · kind B2 · utility

Assignee

• Takeda Pharmaceutical Company Limited · JP

Inventors

• Daniel J. Sexton · Melrose, US
• Ryan Faucette · Melrose, US
• Jon A. Kenniston · Hingham, US
• Gregory P. Conley · Arlington, US
• Andrew Nixon · Hanover, US
• Christopher TenHoor · Hopkinton, US
• Burt Adelman · Concord, US
• Yung Chyung · Lexington, US

Key dates

• Filing date: Jan 17, 2014
• Grant date: Oct 26, 2021
• Expiry date: Jun 4, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.